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a  b  s  t  r  a  c  t
The  Novartis  Vaccines  Institute  for Global  Health  is  developing  vaccines  using  outer  membrane  particles,
known  as  Generalized  Modules  for Membrane  Antigens  (GMMA).  These  are  blebs  of  outer  membrane
and  periplasm,  shed  from  the surface  of  living  Gram-negative  bacteria  following  the targeted  deletion
of  proteins  involved  in  maintaining  the  integrity  of  the  inner  and  outer  membranes.  The  current  study
investigates  the use  of GMMA  as starting  material  for  extraction  of  membrane  components,  focusing
on  the  O-antigen  polysaccharide  portion  of  lipopolysaccharide  from  Salmonella  Typhimurium.  We  show
that the amount  of  O-antigen  extracted  from  GMMA  by  acid  hydrolysis  is  comparable  to  the  quantity
extracted  from  whole  wild  type  bacteria,  but with  less  protein  and  DNA  contaminants.  Compared  to
conventional  puriﬁcation,  GMMA  enabled  a reduction  in the  number  of  puriﬁcation  steps  required  to-antigen
accine
obtain  the  O-antigen  polysaccharide  with  the same  purity.  Puriﬁcation  processes  from  GMMA  and  bacte-
ria were  characterised  by  similar  ﬁnal  yields.  Use  of  GMMA  as starting  material  provides  the  possibility
to simplify  the  puriﬁcation  process  of  O-antigen,  with  a  consequent  decrease  in  manufacturing  costs  of
O-antigen-based  glyconjugate  vaccines  against  Salmonella  strains  and  potentially  other  Gram-negative
bacteria.
©  2015  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
The cell envelopes of Gram-negative bacteria consist of three
ayers: a lipid–protein inner (cytoplasmic) membrane, an outer
embrane, composed mainly of lipopolysaccharides (LPS) and
roteins, and a thin rigid layer of peptidoglycan located in the
eriplasmic space. Peptidoglycan has the ability to interact with
any proteins of the cell envelope, contributing to the stability
f the inner and outer membranes (Godlewska et al., 2009). LPS
onsists of three main components: lipid A, core oligosaccharide
Abbreviations: GMMA,  Generalized Modules for Membrane Antigens; LPS,
ipopolysaccharide; TFF, tangential ﬂow ﬁltration; CDM, chemically deﬁned
edium; HMW,  high molecular weight; MMW,  medium molecular weight; LMW,
ow  molecular weight.
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168-1656/© 2015 The Authors. Published by Elsevier B.V. This is an open access article unand O-speciﬁc polysaccharide (or O-antigen), which is composed of
repeating oligosaccharide units (Vines et al., 2005). The O-antigen
is the most variable part of LPS. Variation between different O-
antigens lies in their sugar composition, the arrangement of sugars,
and the linkages between the sugars within the O-antigen repeating
unit, as well between O-antigen units (Reeves and Wang, 2002).
In nature, Gram-negative bacteria normally shed parts of their
outer membrane as blebs into the surrounding environment
through bulging and ‘pinching off’ of the outer membrane. These
blebs are known as native outer membrane vesicles and have been
proposed as a means of delivering virulence factors to host cells.
Their maximum production occurs during the end of log phase
growth (Kuehn and Kesty, 2005). The blebs are almost free of cyto-
plasmic and inner membrane components and contain lipophilic
proteins. This contrasts with detergent-extracted outer membrane
vesicles derived from homogenized bacteria (Ferrari et al., 2006;
Holst et al., 2009), which have been used as vaccines, e.g. MeNZB,
an outer membrane vesicle vaccine which was  used to control a
Neisseria meningitidis serogroup B outbreak in New Zealand (Holst
et al., 2009).
The spontaneous production of outer membrane particles can
be enhanced by introducing targeted deletion of proteins involved
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Na2HPO4, 24% EtOH (v/v) and 200 mM CaCl2. The solution was
mixed at room temperature for 30 min  then centrifuged for 30 mintolR4 CCGGGTACCGTTGCGCCAGTTTTGCCGCT
tolR5 AGCTTGATATCAAAGCCACGTTGTGTCTCAAAATCTC
tolR6 AGCTTGATATCTGAGGTCTGCCTCGTGAAGAAG
n maintaining the integrity of the inner and outer membranes.
his leads to the production of Generalized Modules for Membrane
ntigens (GMMA). For example, manipulation of the Tol-Pal system
eads to the production of large amounts of GMMA  from Gram-
egative bacteria including Escherichia coli, Shigella and Salmonella
Berlanda et al., 2012). GMMA  are spherical with a bilayer mem-
rane and a variable diameter, depending on the bacterial parent
train. They are composed of outer membrane proteins, LPS, phos-
holipids and soluble periplasmic proteins (Mashburn-Warren
t al., 2008).
Whole GMMA  can either be used as vaccines themselves or as a
ource of components for subunit vaccines. Since GMMA  are com-
osed mainly of membrane components, the puriﬁcation of these
omponents is potentially more straightforward than puriﬁcation
rom whole bacteria. We  hypothesised that simpliﬁed processes
an be used, thereby avoiding costly steps necessary to remove
esidual nucleic acids and proteins that can potentially interfere
ith downstream applications. A main problem with standard
uriﬁcation protocols starting from whole bacteria is the contam-
nation of the end product with nucleic acids and proteins. Each
f these impurities must be consistently removed to an accept-
ble residual level (less than 1% w/w compared to the amount of
ugar) (Micoli et al., 2013) during downstream processing in order
o ensure product safety (Shukla et al., 2008).
NVGH has optimized methods for GMMA  production, using
utant strains with deletion of the tolR gene without loss of mem-
rane integrity (Berlanda et al., 2012), and passage through a
wo-step Tangential Flow Filtration (TFF) process, in order to purify
MMA from bacterial suspensions and soluble proteins (Berlanda
t al., 2012). GMMA  constitute an affordable technology with the
otential to have a marked impact on the manufacturing costs of
accines against Gram-negative bacteria, making them particularly
uitable for the development of low-cost vaccines against neglected
nfectious diseases of the developing world.
In the present study, we investigate the potential of using
MMA from Salmonella Typhimurium SL1344 tolR as a source
f O-antigen polysaccharide for glycoconjugate vaccine production
Micoli et al., 2013).
. Materials and methods
.1. Bacterial strains
Salmonella Typhimurium SL1344 was chosen as the parent
train. S. Typhimurium SL1344 tolR was obtained by replacing
olR (Berlanda et al., 2008) with a kanamycin resistance gene
kan) as follows: The upstream and downstream regions of tolR
ere ampliﬁed using the primer pairs tolR1/tolR2 and tolR3/tolR4
Table 1), respectively. The kan gene was ampliﬁed from pUC4K
Berlanda et al., 2012) using primer pairs tolR5/tolR6 (Table 1).
he fragments were inserted into pBluescript (Stratagene) so that
he kan gene interposed the ﬂanking regions of tolR. The replace-
ent construct (upstream region–kan–downstream region) was
mpliﬁed using the primers tolR1/tolR4 and used to transform
ecombination prone cells of S. Typhimurium produced using
he Lambda phage recombination system (red operon) encodedhnology 198 (2015) 46–52 47
on pAJD433 (Berlanda et al., 2012). pAJD434 was  subsequently
removed from the mutant strain.
2.2. Growth and fermentation condition
S. Typhimurium SL1344 wild type and S. Typhimurium SL1344
tolR were grown to 30 OD in 3 and 3.5 L, respectively, of
chemically deﬁned medium (CDM), using a 5 L fermenter (Sarto-
rius B-plus). Temperature was  maintained at 37 ◦C, pH ﬁxed at
6.7 and controlled with 28% NH4OH, and oxygen saturation set
at 30% and maintained using an agitation controller. The com-
position of the CDM was: 13.3 g/L KH2PO4, 4 g/L (NH4)2HPO4,
1.7 g/L citric acid monohydrate, 1 M MgSO4·7H2O, 1 mL/L Trace
Elements, 1 mL/L Trace Vitamins and 3% glycerol, pH 6.7. Trace Ele-
ments solution contained: 2.5 g/L CoCl2·6H2O, 15 g/L MnCl2·4H2O,
1.5 g/L CuCl2·H2O, 3 g/L H3BO3, 2.5 g/L Na2MoO4·2H2O, 2.5 g/L
Zn(CH3COO)2·H2O and 100 mM ferric citrate. Trace Vitamins
solution contained: 5 g/L thiamine, 10 g/L nicotinic acid, 10 g/L Ca-
panthotenate and 10 g/L Pyridoxine-HCl, 10 mg/L B12. PPG 0.25 g/L
was added to control foam. Histidine was added to the CDM with a
starting concentration of 0.6 g/L and additional CDM medium feed-
ings were carried out during the fermentation process, giving the
ﬁnal histidine addition of 1.2 g/L. Optical density was measured at
600 nm
2.3. Puriﬁcation from total biomass
2.3.1. Biomass direct acid hydrolysis
Two  litres of the 3 L S. Typhimurium SL1344 wild type fermen-
tation broth were directly hydrolysed with 1% Acetic Acid (pH
4–4.5), 100 ◦C, 6 h (Fig. 1A). The resulting solution was neutralized
by adding 28% NH4OH (Sigma, 338818) to a pH of 6–7.
2.3.2. Standard O-antigen puriﬁcation process from wild type
Salmonella
Standard O-antigen puriﬁcation from the hydrolysate was  per-
formed as previously described (Micoli et al., 2013) (Fig. 2A).
At the end of hydrolysis, S. Typhimurium SL1344 wild type fer-
mentation broth was  passed through a 0.2 m TFF membrane
(Hydrosart Sartocon Slice 0.2 m,  Sartorius). 1.8 L of the result-
ing permeate were concentrated ﬁvefold by TFF (Pressure in,
Pin = 1.8–2.0 bar and transmembrane pressure, TMP  = 0.9–1 bar),
using a 30 kDa cut-off ﬁlter cassette (Hydrosart Sartocon Slice 200,
Sartorius), then washed by diaﬁltration against 10 volumes of 1 M
NaCl and then 10 volumes of water, maintaining the same vol-
ume.
Fifty millilitres of the 5× 30 kDa retentate was further processed.
Citrate buffer (200 mM,  pH 2.7) was added, to give a ﬁnal concentra-
tion of 20 mM,  pH 3. The solution was  mixed at room temperature
for 30 min, and further centrifuged for 30 min, at 4000 × g and
4 ◦C, and the resulting pellet was discarded. The O-antigen in the
supernatant was puriﬁed by cationic exchange ﬁltration, using a
Sartobind S MA75 ﬁlter (Sartorius) equilibrated with 20 mM citrate
pH 3 using the same equilibration conditions. In this step, pro-
tein impurities are reduced through the binding of proteins to the
ﬁlter bed, while the O-antigen is eluted in the ﬂow-through. The
ﬂow-through was  collected, and 500 mM Na2HPO4, absolute EtOH
and 5 M CaCl2 were added to give a ﬁnal concentration of 18 mMat 4000 × g and 4 ◦C, and the resulting pellet (formed by nucleic
acid) was  discarded. Five millilitre-aliquots of the supernatant, con-
taining O-antigen, were passed through a PD-10 desalting column
(GE Healthcare Life Sciences) and analysed.
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Fig. 1. Flow chart for O-antigen extraction from S. Typhimurium SL1344 wild type
and  S. Typhimurium SL1344 tolR GMMA.  S. Typhimurium SL1344 wild type was
directly hydrolysed at the end of the fermentation process and then passed through





























tiﬁc Micro BCA Protein Assay Kit), following the manufacturer’s
instructions. Nucleic acid content was estimated measuring theaining O-antigen. Salmonella Typhimurium SL1344 tolR fermentation culture was
rocessed by 0.2 m TFF to collect the permeate containing GMMA, and then hydrol-
sed to release O-antigen.
.4. Puriﬁcation from GMMA
.4.1. GMMA  recovery and direct acid hydrolysis
3.5 L of Salmonella Typhimurium SL1344 tolR fermentation
roth were ﬁltered through a 0.2 m TFF cassette (Sartocon Slice
ydrosart 0.2 m Sartorius) in order to separate the bacterial
iomass from permeate containing GMMA  and soluble proteins
Fig. 1B). 1.8 L of GMMA of the 0.2 m TFF permeate were hydrol-
sed with 1% Acetic Acid (pH 4–4.5), 100 ◦C, 6 h (Fig. 1B). The
esulting solution was neutralized by adding 28% NH4OH (Sigma,
38818) to a pH of 6–7.
.4.2. O-antigen puriﬁcation process from GMMA
1.8 L of hydrolysed GMMA  from the 0.2 m TFF Salmonella
yphimurium SL1344 tolR permeate were concentrated three-
old by TFF (Pin = 1.8–2.0 bar and transmembrane pressure,
MP  = 0.9–1 bar), using a 30 kDa cut-off ﬁlter cassette and the sam-
le washed by diaﬁltration against 10 volumes of 1 M NaCl and then
0 volumes of water, maintaining the same volume. The retentate
as collected, and four aliquots of 50 mL  were prepared and treated
sing various approaches, as described below (Fig. 2A–D).
.4.2.1. Standard O-antigen puriﬁcation process. The sample (50 mL,
liquot 1) was processed according to the standard puriﬁcation
rotocol used for the Salmonella Typhimurium wild type biomass
Section 2.3.2 and Fig. 2, scheme A)..4.2.2. Citrate buffer precipitation and cationic exchange chromatog-
aphy. Citrate buffer (200 mM,  pH 2.7) was added to the 50 mL
liquot 2 giving a ﬁnal concentration of 20 mM,  pH 3. The solu-
ion was mixed at room temperature for 30 min  and centrifugedhnology 198 (2015) 46–52
for 30 min  at 4000 × g and 4 ◦C. The supernatant was  collected and
passed through a Sartobind S MA75 ﬁlter, conditioned with the
same buffer (Citrate buffer 20 mM,  pH 3.0). The ﬂow-through was
collected, passed through a PD-10 desalting column and analysed
(Fig. 2 scheme B, i.e. no EtOH and CaCl2 precipitation step).
2.4.2.3. Citrate buffer and CaCl2/EtOH precipitations. Citrate buffer
(200 mM,  pH 2.7) was  added to the 50 mL  aliquot 3, giving a ﬁnal
concentration of 20 mM,  pH 3. The solution was mixed at room tem-
perature for 30 min  and further centrifuged for 30 min  at 4000 × g
and 4 ◦C. The supernatant was collected and 500 mM Na2HPO4,
absolute EtOH and 5 M CaCl2 were added to give ﬁnal concen-
trations of 18 mM Na2HPO4, 24% EtOH (v/v) and 200 mM CaCl2.
The solution was  mixed at room temperature for 30 min  and fur-
ther centrifuged at 4000 × g at 4 ◦C for 30 min, the supernatant was
collected, passed through a PD-10 desalting column and analysed
(Fig. 2 scheme C, i.e. no cationic exchange chromatography step).
2.4.2.4. Cationic exchange chromatography. Citrate buffer (200 mM,
pH 2.7) was added to 50 mL  aliquot 4, giving a ﬁnal concen-
tration of 20 mM,  pH 3. The resulting solution was immediately
passed through Sartobind S MA75 ﬁlter, conditioned with the same
buffer (Citrate buffer 20 mM,  pH 3.0). The ﬂow-through was  passed
through a PD-10 desalting column and analysed (Fig. 2, scheme D,
i.e. no citrate buffer precipitation and no EtOH/CaCl2 precipitation
steps).
2.5. Analytical size exclusion chromatography: TSK gel 3000
PWXL
Molecular size distribution of O-antigen populations was  mea-
sured as previously described (Micoli et al., 2013). Samples were
analysed by HPLC-Size Exclusion Chromatography, using a TSK gel
3000 PWXL column (30 cm × 7.8 mm;  particle size 7 m). Running
buffer composition was  100 mM NaCl, 100 mM NaH2PO4 5%, CH3CN
pH 7 and the ﬂow rate was  of 0.5 mL/min. The O-antigen peaks were
measured by a refractive index detector.
2.6. High-Performance Anion-Exchange Chromatography with
Pulsed Amperometric Detection (HPAEC-PAD)
Precise sugar quantiﬁcation and composition analysis was  per-
formed by HPAEC–PAD, after acid hydrolysis of the O-antigen to
release the monosaccharides constituting the sugar chain (Micoli
et al., 2013). Commercial monomer sugars were used for prepara-
tion of calibration curves for Rha, Gal, Glc and Man  quantiﬁcation.
O-antigen samples were diluted to have each sugar monomer in
the range 0.5–10 g/mL, and were hydrolysed at 100 ◦C for 4 h in
2 M triﬂuoroacetic acid.
2.7. Determination of total sugar by Phenol Sulphuric Acid
Colorimetric Assay, protein and nucleic acid content of hydrolysed
samples
In process control quantiﬁcation of total sugar in each sample
during the various steps of puriﬁcation was determined by Phe-
nol Sulphuric Acid Colorimetric Assay (Dubois et al., 1951). Protein
content was  measured by the Micro BCA Method (Thermo scien-absorbance at 260 nm,  the maximum absorption wavelength of
DNA. This method gives only an estimate of the upper limit of the
nucleic acid content present in the sample, since at 260 nm other
components (e.g. protein) can contribute some absorbance.



























ing the ﬁrst 30 kDa TFF and citrate buffer addition, the amountig. 2. O-antigen puriﬁcation strategies starting from GMMA.  To optimize the O-a
MMA: (A) GMMA sample was treated using the standard O-antigen puriﬁcation p
ationic exchange chromatography were used; (C) citrate buffer and CaCl2/EtOH p
as  used.
. Results
.1. Composition of initial hydrolyses
Whole S. Typhimurium SL1344 wild type and GMMA  from
almonella Typhimurium SL1344 tolR,  were hydrolysed and then
nalysed for total sugar, peptide and nucleic acid content. No
esicles equivalent to GMMA  could be recovered from the S.
yphimurium SL1344 wild type fermentation broth. Following acid
ydrolysis, the GMMA  preparation had a comparable total sugar
oncentration to the wild type bacteria (0.86 g/L versus 1.0 g/L;
able 2). Hydrolysed material from GMMA  contained much lower
mounts of protein and nucleic acid contamination compared with
aterial from the wild type fermentation culture, particularly with
egards to nucleic acids (Table 2). These samples were analysed by
EC on a TSK gel 3000 PWXL HPLC-SEC column. The material from
hole bacteria (solid line, Fig. 3A) gave three refractive index peaks
orresponding to high molecular weight (HMW), medium molec-
lar weight (MMW)  and low molecular weight (LMW)  O-antigen.
he hydrolysed material from GMMA  (dashed line, Fig. 3A) gave
eaks with a similar elution time but with a relatively lower HMW
-antigen.
.2. O-antigen puriﬁcation from Salmonella Typhimurium
L1344 wild type bacteria and GMMA
Concentrations of sugar, protein and nucleic acids, following
ach step of the standard puriﬁcation process following 0.2 m puriﬁcation protocol, we used different approaches starting with the hydrolysed
ol, already developed for the biomass; (B) only the ﬁrst precipitation step and the
tations were used avoiding the Sartobind S step; (D) only cationic exchange ﬁlter
TFF of hydrolysed wild type bacteria, are given in Table 2. We
have previously veriﬁed good agreement between this assay and
HPAEC-PAD (Micoli et al., 2013). To assess whether contami-
nating nucleic acids could impair performance of the phenol
sulphuric acid assay in the current study, we treated DNA  with
1% Acetic Acid at 100 ◦C for 6 h (the same treatment followed for
O-antigen extraction) and added 62.5 g/mL (ﬁnal concentration),
the equivalent of that present in the most impure intermedi-
ate of the process described in the study, to a standard sample
of glucose at 100 g/mL. Sugar quantiﬁcation varied by a max-
imum of 10% from the concentrations recorded without the
addition of nucleic acids, indicating minimal interference with the
assay.
3.2.1. Standard puriﬁcation of O-antigen from GMMA
Using the standard O-antigen puriﬁcation (Section 2.4.2.1,
Fig. 2, scheme A), no pellet was observed at the end of the pre-
cipitation steps, either the ﬁrst step, using citrate buffer, which
permits the co-precipitation of nucleic acids and proteins, or
the CaCl2/EtOH step indicating the absence of sufﬁcient protein
and nucleic acid for visible precipitation. Very low levels of
nucleic acids were present in the GMMA  sample, and follow-remained the same (Table 2). The content of residual proteins
decreased by almost 50% at the end of the ﬁrst precipitation step
(Table 2), with a 15-fold reduction following cationic exchange
chromatography.
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Table 2
Purity and yield of Salmonella Typhimurium O-antigen through the standard and alternative puriﬁcation processes starting with wild type bacterial biomass or GMMA. The
end  points of each of the four GMMA-derived O-antigen puriﬁcation schemes (A to D) are given in bold.
Step Sugara (mg/L) Proteina (mg/L) Nucleic acida (mg/L) % Proteinb % Nucleic acidsb % Sugar yieldc
Puriﬁcation from biomass
Starting hydrolysate 1000 680 567 68.0 56.7
30  kDa TFF 916 164 570 18.0 62.2
First precipitation, citrate buffer 938 18.0 160 1.9 17.0 102.4
Sartobind S MA75 744 2.8 2.8 0.4 0.4 81.2
Second precipitation CaCl2/EtOH 650 1.6 2.4 0.2 0.3 71.0
Puriﬁcation from GMMA
Starting hydrolysate 860 144 11 16.7 1.2
30  kDa TFF 824 70.7 2.7 8.6 0.4
Standard puriﬁcation
First precipitation, citrate buffer 812 40.7 2.0 5.0 0.3 98.6
Sartobind S MA75 (scheme B) 618 2.7 2.0 0.4 0.3 75.0
Second precipitation, CaCl2/EtOH (scheme A) 514 2.0 2.0 0.4 0.3 62.4
Alternative puriﬁcations (ﬁnal puriﬁcation)
First precipitation citrate buffer and second
precipitation (scheme C)
564 22.0 2.0 3.9 0.3 68.5






















fa Per L of hydrolysate taking into account concentration in TFF steps and volume
b compared to sugar content.
c yield of sugar from 30 kDa hydrolysate.
.2.2. Modiﬁed puriﬁcation of O-antigen from GMMA
Although the ﬁrst precipitation step, citrate buffer 20 mM,  was
nsufﬁcient to meet the target level of residual protein, optimal
uriﬁcation could still be achieved when the ﬁrst citrate pre-
ipitation step was used in combination with cationic exchange
hromatography, without the ﬁnal CaCl2/EtOH precipitation step
Section 2.4.2.2, Fig. 2, scheme B). At the end of these two  steps,
here was very low residual nucleic acid and proteins levels so the
nal precipitation step using the CaCl2/EtOH could be removed
Table 2). A suboptimal result was obtained using just two  precipi-
ation steps (citrate buffer and CaCl2/EtOH) without the Sartobind
 MA75 ﬁltration step (Section 2.4.2.3, Fig. 2, scheme C). The
ig. 3. S. Typhimurium SL1344 wild type and S. Typhimurium SL1344 tolR GMMA
PLC-SEC proﬁles. (A) Following hydrolysis, but prior to puriﬁcation, the refrac-
ive  index channel for S. Typhimurium SL1344 wild type O-antigen (solid line)
ndicates the predominance of the high molecular weight (HMW)  and low molec-
lar weight (LMW)  populations, whereas the main populations for S. Typhimurium
L1344 tolR GMMA (dashed line) are medium molecular weight (MMW)  and LMW
-antigen. (B) At the end of puriﬁcation, LMW  O-antigen is lost as indicated by pro-
les  of pure O-antigen from both starting materials, with continued dominance of
MW  O-antigen starting from wild type bacteria (solid line) and MMW  O-antigen
rom GMMA  (dashed line).ple.
levels of residual proteins and nucleic acids remained higher than
required (Table 2). However using only the Sartobind S MA75 ﬁlter,
without either precipitation step gave a low level of impurities
(Section 2.4.2.4, Fig. 2, scheme D). The amount of sugar in the
cationic exchange chromatography ﬂow though was no lower
than the ﬁnal sugar concentration in the standard puriﬁcation
protocol (Table 2). These data indicate that the cationic exchange
chromatography step is responsible for the main reduction in
impurities, while maintaining an optimum sugar yield, and that
both precipitations steps involved in the O-antigen puriﬁcation
protocol can be removed when the starting material is GMMA.
The ﬁnal yield of O-antigen obtained starting from GMMA  and
using only Sartobind S for protein removal was  approximately
72% and almost identical to the ﬁnal sugar yield obtained from
Salmonella Typhimurium SL1344 wild type bacteria biomass fol-
lowing the standard puriﬁcation process (Table 2).
3.3. O-antigen characterization of O-antigen puriﬁed from GMMA
The GMMA  O-antigen was  characterised for sugar composition
with HPAEC-PAD and the analysis conﬁrmed the expected structure
for Salmonella Typhimurium O-antigen in relation to composition of
the sugar backbone of rhamnose, mannose and galactose (Table 3)
(Micoli et al., 2014). However, glucosylation of O-antigen extracted
from GMMA  was higher than that from wild type Salmonella,  with
a molar ration of 0.49 relative to rhamnose, as compared with 0.08.
Analysis by HPLC-SEC showed that the MMW  population remained
the most abundant one for O-antigen from GMMA,  while the HMW
population was  dominant for O-antigen from wild type. The LMW
fraction was  completely lost following puriﬁcation, regardless of
whether the O-antigen was  extracted from wild type bacteria or
GMMA  (Fig. 3B).
Table 3
Sugar composition of O-antigen from Salmonella Typhimurium SL1344 GMMA and






Man  1.00 1.00
Gal  1.08 1.10
Glc  0.49 0.08





























































Fig. 4. Flow chart of O-antigen puriﬁcation process starting from biomass and
GMMA.  With GMMA from S. Typhimurium SL1344 tolR as starting material, the
O-antigen puriﬁcation process could be simpliﬁed compared with that used for
puriﬁcation from wild type S. Typhimurium SL1344, with the removal of the twoE. Meloni et al. / Journal of 
. Discussion
An ideal vaccine production system, especially for bacterial vac-
ines for developing countries, will encompass multiple antigens
nd enable vaccines to be rapidly tailored to local and changing
ntigenic phenotypes. Ideally, such vaccines will also need to be
nexpensive to manufacture (Berlanda et al., 2012). We  investigated
he use of GMMA  from S. Typhimurium SL1344 tolR,  to under-
tand whether GMMA  could be used as an alternative O-antigen
ource to wild type bacteria for the development of glycoconjugate
accines. Although wild type Gram-negative bacteria can sponta-
eously shed vesicles equivalent to GMMA  (termed native outer
embrane vesicles or NOMV), no such vesicles could be recovered
rom the fermentation broth of wild type S. Typhimurium SL1344.
herefore, the introduction of a modiﬁcation such as the deletion of
olR, described here, is an essential pre-requisite for the production
f GMMA  from S. Typhimurium.
GMMA from Salmonella Typhimurium SL1344 tolR has two
ain characteristics at the end of the fermentation process, relating
o the polysaccharide yield and impurities: The O-antigen concen-
ration using GMMA  as starting material is comparable with that
sing Salmonella Typhimurium SL1344 wild type biomass (respec-
ively 1.56 g versus 1.80 g per 1.8 L of acid hydrolysate), but a lower
mount of impurities is present in the GMMA  preparation com-
ared with the SL1344 wild type biomass (Table 2), indicating
he potential of GMMA  as starting material for O-antigen extrac-
ion. First, we applied the standard O-antigen puriﬁcation protocol
n GMMA.  This method of O-antigen extraction from biomass
nvolves several puriﬁcation steps, which are required to remove
arge quantities of impurities consistently, present at the end of
he initial acid hydrolysis step, as reported by Micoli et al. (2013).
e have shown that, owing to the low level of impurities present
n GMMA,  this puriﬁcation protocol can be simpliﬁed, removing
he citrate buffer and CaCl2/EtOH precipitation steps (Fig. 4) and
eaving only the cation exchange ﬁltration step for removal of
mpurities.
A maximum acceptable limit for nucleic acid and protein con-
amination in O-antigen-based Salmonella conjugate vaccines has
et to be stipulated (Kothari et al., 2014). We  decided to set our
pper limits for puriﬁed O-antigen from S. Typhimurium in the
urrent study at 1% for both protein and nucleic acid content. These
alues are guided by the limits speciﬁed by the WHO  of 1% (w/w
ith respect to polysaccharide content) protein and 2% (w/w with
espect to polysaccharide content) nucleic acids for Salmonella Vi
accines (WHO, 1994).
Starting from GMMA  we obtained the same sugar yield as for
he Salmonella Typhimurium SL1344 per litre of the fermentation
around 71%) using a TFF ﬁltration step, to separate the GMMA-
ontaining supernatant in the culture from the bacterial cells, and
ydrolysis, followed by a TFF and a cation ﬁltration step to remove
mpurities. From a bioprocess view, this compares very favourably
ith the best process previously developed for puriﬁcation from
hole bacterial cultures, comprising an acid hydrolysis step, TFF,
recipitation and centrifugation, a cation ﬁltration step and another
recipitation and centrifugation step.
Associated with the generation of the GMMA  producing strain,
here was a change in the relative size of the O-antigen, with rel-
tively more MMW  and less HMW.  Although this is not a direct
onsequence of the revised puriﬁcation process (the ratios of HMW
nd MMW  were similar following hydrolysis and after puriﬁca-
ion), the lower size results in a lower viscosity of the puriﬁed
olysaccharide, and therefore leads to improvements in the sub-
equent vaccine production. In addition, the more homogeneous
-antigen population improves consistency and characterisation of
he ﬁnal conjugate. We  have recently shown that glycoconjugate
accine made with MMW  O-antigen population of S. Typhimuriumprecipitation steps, giving advantages in terms of time and cost, thus potentially
reducing the unit vaccine cost.
is more immunogenic than an equivalent vaccine made with HMW
O-antigen (Rondini et al., 2014).
Another difference between the O-antigen extracted from
GMMA  and that from wild type Salmonella is the glucosylation level
of the puriﬁed O-antigen, with O-antigen from GMMA being over
ﬁve times more glucosylated. In our recent work on S. Typhimurium
O-antigen conjugate vaccines, we found that higher O-antigen glu-
cosylation associated with greater immunogenicity (Rondini et al.,
2014). These differences in relation to O-antigen size population
and glucosylation level suggest additional potential beneﬁts from
using GMMA  as the starting source of O-antigen for production
of S. Typhimurium glycoconjugate vaccines. Further studies are
required to understand what impact use of GMMA as starting mate-
rial would have on O-antigen of other Salmonella strains and other
Gram-negative bacteria.A surprising result was  the amount of GMMA  in the supernatant
of the bacterial culture. There was  1.0 g/L of sugar in the hydrolysate
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rom just the GMMA  of the GMMA-producing bacteria. The yield
f O-antigen as a percentage of the total sugar was similar from
iomass and GMMA, suggesting that there is nearly as much LPS,
nd presumably outer membrane per litre in the GMMA  alone from
tolR mutant bacteria, as there is in wild type bacteria.
In summary, GMMA  have good potential for use as a starting
ource for O-antigen extraction, owing to both the large quantity
f GMMA in cultures from mutant bacteria and the possibility of
impliﬁcation of the standard puriﬁcation process, with a reduc-
ion in production time and cost, ultimately leading to a decrease
n the potential cost of the ﬁnal vaccine. Suitability of the pro-
ess at manufacturing scale could facilitate the robust generation
f polysaccharide-based vaccines starting from GMMA, as the
embrane component source, and reduce the manipulation of
otentially pathogenic bacteria, with a consequent safety beneﬁt
uring the O-antigen extraction process.
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